Pharmacist and Biochemical specializing in obtaining recombinant viral and bacterial proteins targets, in prokaryotic and eukaryotic systems for studies and development of diagnostic methods and vaccines. Registered with the Class Council (CRF-SP). PhD in Sciences by the Biology of the Host Pathogen Relation program (CAPES 7), Institute of Biomedical Sciences at USP, with a project aimed at the development of a vaccine against the ZIKA virus based on a delivery system composed of lipid vesicles as a delivery system for protein antigens from Zika in a murine model. The master's degree held by the same program at ICB/USP was directed towards the development of a vaccine formulation capable of conferring protection against type 2 Shiga toxin. clinical isolates from positive C. difficile patients, evaluation of infection by multiple strains and susceptibility to antibiotics and development of ELISA for toxin dosage in fecal samples. Collaborating researcher at the Vaccine Development Laboratory at the Microbiology Department of ICB/USP and founding partner of Startup DeltaLys Biotechnology, a spin-off with DNA USP aimed at the commercialization of recombinant proteins. ORCID: https://orcid.org/0000-0002-5434-1674 (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Currently, serological tests for antibodies detection that indicate previous infection by the dengue virus (DENV) are compromised by cross-reactivity with Zika virus antigens (ZIKV). In addition, there is no product commercially available products that differentiate DENV types (1 to 4) that patients were previously exposed to. This proposal aims to optimize the methodology for obtaining i…
This project aims to develop a vaccine strategy for prophylactic against haemolytic uremic syndrome (HUS), the most severe sequelae associated with infection by strains of enterohaemorrhagic Escherichia coli (EHEC). The disease is directly associated with the production of the toxin Stx2, particularly by EHEC strains of serotype O157: H7. The proposal is based on a formulation comprised o…
Stx toxin produced by strains of E. enterohaemorrhagic E. coli (EHEC), particularly by strains of serotype O157: H7 is responsible for leading sequel associated with infection, Hemolytic Uremic Syndrome (HUS), with high rates of mortality and morbidity. There are no therapies or preventive treatments against SHU but several vaccine strategies are being researched for disease control. In t…
| 1 / 1 | Completed research grants |
| 4 / 3 | Completed scholarships in Brazil |
| 5 / 4 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID
Google Scholar Citations